Welcome to our dedicated page for Gaxos.AI SEC filings (Ticker: GXAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Gaxos.ai Inc. (GXAI) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. As a Nasdaq Capital Market issuer and an emerging growth company, Gaxos submits reports and proxy materials that describe its governance, shareholder votes, equity plans, and other material events.
Key filings for Gaxos.ai include Form 10-K annual reports and Form 10-Q quarterly reports, which present audited and interim financial statements, risk factors, and management’s discussion of operations. Investors can use these documents to understand how the company’s AI platforms, subscription models, and sector focus are reflected in its financial reporting and disclosures.
Current reports on Form 8-K capture significant events such as the results of annual meetings, changes in corporate structure, or other material developments. For example, Gaxos has filed an 8-K describing the outcomes of shareholder votes on director elections, ratification of its independent registered public accounting firm, and amendments to its 2022 Omnibus Equity Incentive Plan.
The company’s proxy statements (DEF 14A) provide detail on board composition, executive and director compensation, equity incentive plans, and the specific proposals presented to shareholders at the annual meeting. These documents also outline the procedures for voting, record dates, and meeting logistics.
On Stock Titan, Gaxos.ai filings are updated in near real time as they appear on EDGAR. AI-powered summaries help explain long and complex filings by highlighting key topics such as equity plan changes, auditor ratification, and governance matters, allowing users to quickly identify the sections most relevant to their analysis.
Gaxos.ai (GXAI) reported Q3 2025 results. Revenue reached $498,271, up sharply from $2,704 a year ago, driven mainly by RNK Health’s non‑clinical patient support services. Operating expenses were $1,813,026, reflecting increased selling, general and administrative spending and continued R&D. Net loss attributable to common shareholders was $1,001,474.
For the nine months, revenue totaled $692,974. Other income contributed $173,882 in the quarter, including $156,034 of interest income. As of September 30, 2025, cash was $914,183 and short‑term investments were $12,058,377; working capital was $12,968,843. Management states existing liquidity is expected to fund operations for the next twelve months.
The company expanded its software assets, recording intangible assets, net, of $763,233 after purchasing software in February 2025 for $500,000 in cash and 200,000 shares. Common shares outstanding were 7,123,453 as of November 13, 2025.
Gaxos.ai Inc. held its 2025 annual meeting of stockholders with 2,538,104 shares represented, constituting a quorum. All four director nominees were elected to serve until the next annual meeting; For votes for the nominees ranged from 592,411 to 609,602, with 1,905,954 broker non-votes recorded on the director elections. Stockholders ratified the appointment of Salberg & Company, P.A. as the independent auditor for fiscal 2025 by a vote of 2,274,665 For, 246,475 Against, and 16,964 Abstain. Shareholders also approved an amendment to the 2022 Omnibus Equity Incentive Plan to increase reserved shares from 553,637 to 803,637; the vote on the amendment was 507,255 For, 122,893 Against, 2,002 Abstain, with 1,905,954 broker non-votes.
Gaxos.ai reported initial commercial revenue while continuing product investments and recording operating losses. Revenue was $170,971 in Q2 2025 and $194,703 for the six months, driven primarily by RNK Health administrative services ($170,398 Q2; $192,950 six months). The company recorded a net loss of $824,572 for the quarter and $2,056,634 year-to-date, driven by research and development and general and administrative costs of $1,153,665 in Q2.
On the balance sheet, cash declined to $1,718,964 from $14,398,099 at December 31, 2024, after purchasing short-term investments that rose to $12,326,666. Working capital remained positive at $13,992,440, and management states these resources should be sufficient to meet operating needs for the next 12 months. The company recorded a $748,000 intangible asset acquisition funded with $500,000 cash and 200,000 shares valued at $248,000.
FAQ
What is the current stock price of Gaxos.AI (GXAI)?
What is the market cap of Gaxos.AI (GXAI)?
